Livzon Pharmaceutical Group Inc. (LVZPF) Stock

About Livzon Pharmaceutical Group Inc.

Livzon Pharmaceutical Group Inc., founded in 1985 and based in Zhuhai, China, is dedicated to the research, development, manufacturing, and distribution of a wide array of pharmaceutical products, active pharmaceutical ingredients (APIs), and related intermediates. The company's diverse range of medications includes Ilaprazole enteric-coated tablets for treating duodenal ulcers and reflux esophagitis, and Laprazole sodium for injection to manage peptic ulcer hemorrhage. It also offers Leuprorelin Acetate Microspheres for injection and Urofollitropin for injection to address anovulation and other fertility concerns. Psychiatric conditions are covered by Perospirone Hydrochloride for schizophrenia, while respiratory ailments benefit from Anti-viral Granules for upper respiratory tract infections and influenza. Furthermore, its traditional Chinese medicine offerings feature Shenqi Fuzheng Injection, used to alleviate general weakness, tiredness, lassitude, spontaneous sweating, and vertigo, and is also beneficial for patients with lung and stomach cancer. Beyond therapeutic drugs, Livzon Pharmaceutical Group also produces a variety of diagnostic reagents. These encompass kits for detecting IgM/IgG antibodies to coronavirus, nucleic acid test kits for human immunodeficiency virus type 1 (HIV-1), antinuclear antibody test kits, interferon-gamma release assays, and rapid tests for Mycoplasma pneumoniae IgM antibodies. The company's comprehensive portfolio extends to biochemical drugs, microbiological preparations, biologics, traditional Chinese drug preparations, pharmaceutical raw materials, and various antibiotics. While its primary operations are within the People's Republic of China, Livzon Pharmaceutical Group also engages in the export of its products internationally.

Livzon Pharmaceutical Group Inc. is headquartered in CN.

Livzon Pharmaceutical Group Inc. (LVZPF) stock trades at $5.22 with a market capitalization of $6.06B. The stock is valued at a price-to-earnings (P/E) ratio of 13.77, price-to-book of 1.87, price-to-sales of 2.32. Over the past 52 weeks the stock has ranged between $3.43 and $5.22, and currently trades at its 52-week high. It pays a dividend yielding 4.02%.

On profitability, Livzon Pharmaceutical Group Inc. generates a return on equity (ROE) of 13.95%, above the typical market average, return on capital employed of 16.38%, an operating margin of 22.67%, a net profit margin of 16.77%.

Official website: www.livzon.com.cn